DEVELOPMENT OF NOVEL HYDROQUINONE-BASED SERCA INHIBITORS

新型氢醌 SERCA 抑制剂的开发

• 批准号: 7610397
• 负责人: Stefan Franz Paula
• 金额: $ 1.45万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7610397
• 关键词: Ca(2+)-Transporting ATPase; Chemotherapy-Oncologic Procedure; Computational Technique; Computer Retrieval of Information on Scientific Projects Database; Development; Endoplasmic Reticulum; Enzyme Inhibitor Drugs; Enzyme Inhibitors; Enzymes; Funding; Goals; Grant; Hydroquinones; Institution; Research; Research Personnel; Resources; Source; United States National Institutes of Health; base; hydroquinone; inhibitor/antagonist; novel; tool

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of the proposed research is to initiate the development of novel inhibitors of the enzyme sarco-endoplasmic reticulum calcium ATPase (SERCA) using a combination of experimental and computational techniques. Not only are SERCA inhibitors powerful tools for the study of the enzyme's function, but they are also believed to be of potential medicinal value for cancer chemotherapy.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 拟议的研究的总体目标是使用实验和计算技术的组合来启动酶Sarco-肾上腺钙钙ATPase（SERCA）的新型抑制剂的发展。 SERCA抑制剂不仅是研究酶功能的强大工具，而且还被认为对癌症化学疗法具有潜在的药用价值。